Clarification of Block Admission Application (6374J)

TIDMMEDG TIDMMEDU

RNS Number : 6374J

Medgenics Inc

01 July 2011

Medgenics, Inc.

(the "Company")

Clarification of Block Admission Application

1 July 2011

Medgenics, Inc. (NYSE Amex: MDGN and MDGN.W and London Stock Exchange - AIM: MEDG and MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, clarifies the information given in its announcement of 8 June 2011 with respect to a block admission application. The Company has made an application for a block admission, in accordance with the AIM Rules, for 963,119 common shares of par value U.S. $0.0001 each in the Company ("Common Shares") under the MEDG line and 963,119 Common Shares under the MEDU line (in relation to the Company's outstanding warrants and options under its share incentive plans), which together represent approximately 20% of the Company's currently issued share capital. It is now expected that this block admission will be effective from 6 July 2011.

For further information, contact:

 
Medgenics, Inc.                       Phone: [phone] 
 Dr. Andrew L. Pearlman 
Religare Capital Markets (Nominated   Phone: [phone] 
 Adviser) 
 James Pinner 
 Derek Crowhurst 
SVS Securities plc (Joint Broker)     Phone: [phone] 
 Ian Callaway 
Nomura Code Securities PLC (Joint     Phone: [phone] 
 Broker) 
 Jon Senior 
De Facto Financial                    Phone: [phone] 
 Mike Wort 
 Anna Dunphy 
Lippert/Heilshorn & Associates, Inc.  Phone: [phone] 
 (Investment Relations - US) 
 Anne Marie Fields 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

LISKMGGNDMRGMZM